interestingly COAST reports ph3 first in early Q2 2025 which is trial with eyelea - eyelea has $6B+ in sales and from memory OPT p2b in comparison to eyelea was better result than against lucentis (which only does about $1.5B of sales p.a)
So all in all - it’s the first trial result which will make or break this company
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| OPT (ASX) Chart |
Day chart unavailable